ArticleCancer research2017
EGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.
0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed
8.8field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 82 citations in OpenAlex.
- Dissociated Response to Immune Checkpoint Inhibition in Head and Neck Squamous Cell Carcinoma Is Common and Exhibits Distinct Clinical Outcomes.Cancer research communications · 2026Article
- Modeling acquired TKI resistance and effective combination therapeutic strategies in murine RET+ lung adenocarcinoma.Cancer letters · 2026Article
- Oligoprogression in NSCLC with Other Actionable Oncogenic Drivers Beyond EGFR and ALK: An Emerging Entity.International journal of molecular sciences · 2026Review
- BRAFbioRxiv : the preprint server for biology · 2025Article
- Oncogenic EML4-ALK assemblies suppress growth factor perception and modulate drug tolerance.Nature communications · 2024Article
- Review
- Current treatment and novel insights regarding ROS1-targeted therapy in malignant tumors.Cancer medicine · 2024Review
- SOS2 modulates the threshold of EGFR signaling to regulate osimertinib efficacy and resistance in lung adenocarcinoma.Molecular oncology · 2024Article
- Differential network analysis of ROS1 inhibitors reveals lorlatinib polypharmacology through co-targeting PYK2.Cell chemical biology · 2024Article
- Article
- MIG6 Mediates Adaptive and Acquired Resistance to ALK/ROS1 Fusion Kinase Inhibition through EGFR Bypass Signaling.Molecular cancer therapeutics · 2024Article
- Research progress on the role of bypass activation mechanisms in resistance to tyrosine kinase inhibitors in non-small cell lung cancer.Frontiers in oncology · 2024Review
- SOS1 and KSR1 modulate MEK inhibitor responsiveness to target resistant cell populations based on PI3K and KRAS mutation status.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- A functional sgRNA-CRISPR screening method for generating murine RET and NTRK1 rearranged oncogenes.Biology open · 2023Article
- SOS2 regulates the threshold of mutantbioRxiv : the preprint server for biology · 2023Article
- The heterogeneous transition state of resistance to RET kinase inhibitors converges on ERK1/2-driven Aurora A/B kinases.Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy · 2023Article
- A Rapid, Functional sgRNA Screening Method for Generating Murine RET and NTRK1 Fusion Oncogenes.bioRxiv : the preprint server for biology · 2023Article
- Yes-associated protein 1 mediates initial cell survival during lorlatinib treatment through AKT signaling in ROS1-rearranged lung cancer.Cancer science · 2023Article
- Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAFV600E-Driven Lung Tumorigenesis.Cancer research · 2022Article
- Ttc39c is a potential target for the treatment of lung cancer.BMC pulmonary medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 2 institutions in 1 country.
Aria VaishnaviDivision of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado.
Laura SchubertDivision of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado.
Uwe RixDepartment of Drug Discovery, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
Lindsay A MarekDepartment of Craniofacial Biology, University of Colorado School of Dental Medicine, Aurora, Colorado.
Anh T LeDivision of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado.
Stephen B KeysarDivision of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado.
Magdalena J GlogowskaDivision of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado.
Matthew A SmithDepartment of Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
Severine KakoDivision of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado.
Natalia J SumiDepartment of Drug Discovery, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
Kurtis D DaviesDepartment of Pathology, University of Colorado School of Medicine, Aurora, Colorado.
Kathryn E WareDepartment of Craniofacial Biology, University of Colorado School of Dental Medicine, Aurora, Colorado.
Marileila Varella-GarciaDivision of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado.
Eric B HauraDepartment of Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
Antonio JimenoDivision of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado.
Lynn E HeasleyDepartment of Craniofacial Biology, University of Colorado School of Dental Medicine, Aurora, Colorado.
Dara L AisnerDepartment of Pathology, University of Colorado School of Medicine, Aurora, Colorado.
Robert C DoebeleDivision of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado. robert.doebele@ucdenver.edu.
University of Colorado Denver · USMoffitt Cancer Center · US
Funding
University of Colorado Cancer Center Support Grant - Lung Cancer Patient-Derived Xenografts with Autologous Human Immune SystemsP30CA046934 · NCI · UNIVERSITY OF COLORADO DENVER · PI James V Degregori · 1988 to 2026
$117.0MTRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI KENNETH Lynn WRIGHT · 1998 to 2026
$93.5MTissue Bank and Biomarkers CoreP50CA058187 · NCI · UNIVERSITY OF COLORADO DENVER · PI MILLER, YORK E · 1992 to 2018
$43.8MColorado Clinical and Translational Science Institute (UL1)UL1TR000154 · NCATS · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2012 to 2013
$20.4MPaul Calabresis Award in Clinical Oncology ResearchK12CA086913 · NCI · UNIVERSITY OF COLORADO DENVER · PI VIRGINIA F. BORGES, Jill E Slansky · 2000 to 2026
$17.8MTraining Program in Cancer BiologyT32CA190216 · NCI · UNIVERSITY OF COLORADO DENVER · PI Craig T. Jordan · 2016 to 2026
$3.5MHarnessing beneficial off-target effects of kinase inhibitors in lung cancerR01CA181746 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI RIX, UWE · 2015 to 2019
$2.3MThe role of EGFR as a mechanism of therapeutic resistance in gene fusion positive lung cancer.R01CA193935 · NCI · UNIVERSITY OF COLORADO DENVER · PI DOEBELE, ROBERT C · 2016 to 2020
$2.0MAN ACTIVE ROLE OF ADAPTOR PROTEINS IN TYROSINE KINASE INHIBITOR RESISTANCER21CA181848 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI HAURA, ERIC B. · 2014 to 2015
$403kNCATS NIH HHS UL1 TR000154NCI NIH HHS K12 CA086913NCI NIH HHS P30 CA046934NCI NIH HHS P30 CA076292NCI NIH HHS P50 CA058187NCI NIH HHS R01 CA181746NCI NIH HHS R01 CA193935NCI NIH HHS R21 CA181848NCI NIH HHS T32 CA190216
Abstract
Oncogenic kinase fusions of
Indexed as
AnimalsCarcinoma, Non-Small-Cell LungCell Line, TumorCell ProliferationErbB ReceptorsHEK293 CellsHumansLung NeoplasmsMaleMiceMice, NudeOncogene Proteins, FusionSignal TransductionSmall Molecule LibrariesXenograft Model Antitumor AssaysEGFR protein, humanErbB ReceptorsOncogene Proteins, FusionSmall Molecule Libraries
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.